(Source: MARKETWIRE)Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) announced today that it has closed its previously announced public offering of 3,000,000 shares of its common stock at a price of $34.50 per share. On September 29, 2009, Jefferies & Company, acting as the sole book-running manager of the offering, exercised in full its over-allotment option to purchase an additional 450,000 shares of common stock. The exercise of the option increased the size of the offering to an aggregate of 3,450,000 shares of common stock.

Auxilium received proceeds, net of offering expenses and underwriting discounts and commissions, of approximately $115.7 million. Auxilium offered the shares of its common stock sold in the offering pursuant to a Registration Statement on Form S-3 (Reg. No. 333-133477) filed with the Securities and Exchange Commission on August 27, 2007 and declared effective on September 19, 2007.

Auxilium expects to use the net proceeds from the sale of the shares of its common stock sold in the offering for general corporate purposes, including working capital, product development and capital expenditures.

Copies of the final prospectus supplement and related prospectus may be obtained from Jefferies & Company, Inc., Attention: Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022 or at (888) 449-2342.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Auxilium

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing to urologists, endocrinologists, orthopedists and select primary care physicians. Auxilium markets Testim(R) 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and marketing team. Auxilium has five projects in clinical development. XIAFLEX(TM) (collagenase clostridium histolyticum), formerly referred to as AA4500, has completed phase III clinical trials for the treatment of Dupuytren's contracture, and the biologics license application is under review at the FDA for the treatment of Dupuytren's contracture. XIAFLEX is in phase IIb of development for the treatment of Peyronie's disease and is in phase II of development for treatment of Frozen Shoulder syndrome (Adhesive Capsulitis).